[1] WANG W，JIANG B，SUN H，et al. Prevalence，

incidence，and mortality of stroke in China：results

from a nationwide population-based survey of

480 687 adults[J]. Circulation，2017，135（8）：759-

771.

[2] 中国卒中学会科学声明专家组. 急性缺血性卒中静

脉溶栓：中国卒中学会科学声明[J]. 中国卒中杂志，

2017，12（3）：267-284.

[3] DONG Q，DONG Y，LIU L，et al. The Chinese

Stroke Association scientific statement：intravenous

thrombolysis in acute ischaemic stroke[J]. Stroke

Vasc Neurol，2017，2（3）：147-159.

[4] KIM J T，FONAROW G C，SMITH E E，et al.

Treatment With Tissue Plasminogen Activator in the

Golden Hour and the Shape of the 4. 5-Hour Time-

Benefit Curve in the National United States Get With

The Guidelines-Stroke Population[J]. Circulation，

2017，135（2）：128-139.

[5] SEVER P S，DAHLÖF B，POULTER N R，et

al. Prevention of coronary and stroke events

with atorvastatin in hypertensive patients who

have average or lower-than-average cholesterol

concentrations，in the Anglo-Scandinavian Cardiac

Outcomes Trial--Lipid Lowering Arm（ASCOTLLA）：

a multicentre randomised controlled trial[J].

Lancet，2003，361（9364）：1149-1158.

[6] HASSAN Y，AL-JABI S W，AZIZ N A，et al. Effect

of prestroke use of angiotensin-converting enzyme

inhibitors alone versus combination with antiplatelets

and statin on ischemic stroke outcome[J]. Clin

Neuropharmacol，2011，34（6）：234-240.

[7] HITMAN G A，COLHOUN H，NEWMAN C，et

al. Stroke prediction and stroke prevention with

atorvastatin in the Collaborative Atorvastatin

Diabetes Study（CARDS）[J]. Diabet Med，2007，24

（12）：1313-1321.

[8] COLHOUN H M，BETTERIDGE D J，

DURRINGTON P N，et al. Primary prevention of

cardiovascular disease with atorvastatin in type 2

diabetes in the Collaborative Atorvastatin Diabetes

Study（CARDS）：multicentre randomised placebocontrolled

trial[J]. Lancet，2004，364（9435）：685-

696.

[9] COLLINS R，ARMITAGE J，PARISH S，et al.

MRC/BHF Heart Protection Study of cholesterollowering

with simvastatin in 5963 people with

diabetes：a randomised placebo-controlled trial[J].Lancet，2003，361（9374）：2005-2016.

[10] NAKAYA N，MIZUNO K，OHASHI Y，et al.

Low-dose pravastatin and age-related differences

in risk factors for cardiovascular disease in

hypercholesterolaemic Japanese：analysis of the

management of elevated cholesterol in the primary

prevention group of adult Japanese（MEGA study）

[J]. Drugs Aging，2011，28（9）：681-692.

[11] MATSUSHIMA T，NAKAYA N，MIZUNO K，et

al. The effect of low-dose pravastatin in metabolic

syndrome for primary prevention of cardiovascular

disease in Japan：a post hoc analysis of the MEGA

study[J]. J Cardiovasc Pharmacol Ther，2012，17（2）：

153-158.

[12] WATERS D D，LAROSA J C，BARTER P，et al.

Effects of high-dose atorvastatin on cerebrovascular

events in patients with stable coronary disease in the

TNT（treating to new targets）study[J]. J Am Coll

Cardiol，2006，48（9）：1793-1799.

[13] MILLS E J，O'REGAN C，EYAWO O，et al.

Intensive statin therapy compared with moderate

dosing for prevention of cardiovascular events：a

meta-analysis of >40 000 patients[J]. Eur Heart J，

2011，32（11）：1409-1415.

[14] ZHAO S P，YU B L，PENG D Q，et al. The effect of

moderate-dose versus double-dose statins on patients

with acute coronary syndrome in China：Results of

the CHILLAS trial[J]. Atherosclerosis，2014，233

（2）：707-712.

[15] CANNON C P，BLAZING M A，GIUGLIANO R P，

et al. Ezetimibe added to statin therapy after acute

coronary syndromes[J]. N Engl J Med，2015，372

（25）：2387-2397.

[16] EISEN A，CANNON C P，BLAZING M A，et al.

The benefit of adding ezetimibe to statin therapy

in patients with prior coronary artery bypass

graft surgery and acute coronary syndrome in the

IMPROVE-IT trial[J]. Eur Heart J，2016，37（48）：

3576-3584.

[17] RIDKER P M，DANIELSON E，FONSECA F A，et

al. Rosuvastatin to prevent vascular events in men

and women with elevated C-reactive protein[J]. N

Engl J Med，2008，359（21）：2195-2207.

[18] RIDKER P M，MACFADYEN J G，

NORDESTGAARD B G，et al. Rosuvastatin

for primary prevention among individuals with

elevated high-sensitivity c-reactive protein and 5%

to 10% and 10% to 20% 10-year risk. Implications

of the Justification for Use of Statins in Prevention：

an Intervention Trial Evaluating Rosuvastatin

（JUPITER）trial for "intermediate risk"[J]. Circ

Cardiovasc Qual Outcomes，2010，3（5）：447-452.

[19] TAYLOR F，HUFFMAN M D，MACEDO A F，et al.

Statins for the primary prevention of cardiovascular

disease[J/OL]. Cochrane Database Syst Rev，2013，

（1）：CD004816. http：//cochranelibrary-wiley.com/

doi/10.1002/14651858.CD004816.pub5/abstract;jse

ssionid=531B642963A49795A5C67C417A999369.

f01t02. DOI：10.1002/14651858.CD004816.pub5.

[20] Cholesterol Treatment Trialists（' CTT）Collaborators，

MIHAYLOVA B，EMBERSON J，et al. The effects

of lowering LDL cholesterol with statin therapy in

people at low risk of vascular disease：meta-analysis

of individual data from 27 randomised trials[J].

Lancet，2012，380（9841）：581-590.

[21] TONELLI M，LLOYD A，CLEMENT F，et al.

Efficacy of statins for primary prevention in people

at low cardiovascular risk：a meta-analysis[J/OL].

CMAJ，2011，183（16）：E1189-E1202. https：//doi.

org/10.1503/cmaj.101280.

[22] THANASSOULIS G，WILLIAMS K，ALTOBELLI

K K，et al. Individualized statin benefit for

determining statin eligibility in the primary

prevention of cardiovascular disease[J]. Circulation，

2016，133（16）：1574-1581.

[23] HELLER D J，COXSON P G，PENKO J，et al.

Evaluating the impact and cost-effectiveness of statin

use guidelines for primary prevention of coronary

heart disease and stroke[J]. Circulation，2017，136

（12）：1087-1098.

[24] GREISENEGGER S，MÜLLNER M，

TENTSCHERT S，et al. Effect of pretreatment

with statins on the severity of acute ischemic

cerebrovascular events[J]. J Neurol Sci，2004，221

（1-2）：5-10.

[25] CHOI J C，LEE J S，PARK T H，et al. Effect of

pre-stroke statin use on stroke severity and early

functional recovery：a retrospective cohort study[J/

OL]. BMC Neurol，2015，15：120. https：//doi.

org/10.1186/s12883-015-0376-3.

[26] DESMAELE S，CORNU P，BARBÉ K，et al.

Relationship between pre-stroke cardiovascular

medication use and stroke severity[J]. Eur J Clin

Pharmacol，2016，72（4）：495-502.

[27] ISHIKAWA H，WAKISAKA Y，MATSUO R，et

al. Influence of statin pretreatment on initial

neurological severity and short-term functional

outcome in acute ischemic stroke patients：the

Fukuoka Stroke Registry[J]. Cerebrovasc Dis，2016，

42（5-6）：395-403.

[28] MARTÍ-FÀBREGAS J，GOMIS M，ARBOIX A，et

al. Favorable outcome of ischemic stroke in patients pretreated with statins[J]. Stroke，2004，35（5）：

1117-1121.

[29] ABOA-EBOULÉ C，BINQUET C，JACQUIN A，et

al. Effect of previous statin therapy on severity and

outcome in ischemic stroke patients：a populationbased

study[J]. J Neurol，2013，260（1）：30-37.

[30] ASLANYAN S，WEIR C J，MCINNES G T，et al.

Statin administration prior to ischaemic stroke onset

and survival：exploratory evidence from matched

treatment-control study[J]. Eur J Neurol，2005，12

（7）：493-498.

[31] HASSAN Y，AL-JABI S W，AZIZ N A，et al. Statin

use prior to ischemic stroke onset is associated with

decreased in-hospital mortality[J]. Fundam Clin

Pharmacol，2011，25（3）：388-394.

[32] TSIVGOULIS G，KATSANOS A H，SHARMA V

K，et al. Statin pretreatment is associated with better

outcomes in large artery atherosclerotic stroke[J].

Neurology，2016，86（12）：1103-1111.

[33] TZIOMALOS K，GIAMPATZIS V，BOUZIANA

S D，et al. Effect of prior treatment with different

statins on stroke severity and functional outcome at

discharge in patients with acute ischemic stroke[J/

OL]. Int J Stroke，2013，8（7）：E49. https：//doi.

org/10.1111/ijs.12116.

[34] REEVES M J，GARGANO J W，LUO Z，et al.

Effect of pretreatment with statins on ischemic

stroke outcomes[J]. Stroke，2008，39（6）：1779-

1785.

[35] Alvarez-Sabin J，Huertas R，Quintana M，et al.

Prior statin use may be associated with improved

stroke outcome after tissue plasminogen activator[J].

Stroke，2007，38（3）：1076-1078.

[36] MARTINEZ-RAMIREZ S，DELGADOMEDEROS

R，MARIN R，et al. Statin pretreatment

may increase the risk of symptomatic intracranial

haemorrhage in thrombolysis for ischemic stroke：

results from a case-control study and a metaanalysis[

J]. J Neurol，2012，259（1）：111-118.

[37] NICHOLAS J S，SWEARINGEN C J，THOMAS J

C，et al. The effect of statin pretreatment on infarct

volume in ischemic stroke[J]. Neuroepidemiology，

2008，31（1）：48-56.

[38] OVBIAGELE B，SAVER J L，STARKMAN S，et

al. Statin enhancement of collateralization in acute

stroke[J]. Neurology，2007，68（24）：2129-2131.

[39] YI X，HAN Z，WANG C，et al. Statin and aspirin

pretreatment are associated with lower neurological

deterioration and platelet activity in patients with

acute ischemic stroke[J]. J Stroke Cerebrovasc Dis，

2017，26（2）：352-359.

[40] TSAI N W，LIN T K，CHANG W N，et al. Statin

pre-treatment is associated with lower platelet

activity and favorable outcome in patients with acute

non-cardio-embolic ischemic stroke[J/OL]. Crit Care，

2011，15（4）：R163. https：//doi.org/10.1186/cc10303.

[41] SAFOURIS A，KROGIAS C，SHARMA V K，et

al. Statin pretreatment and microembolic signals in

large artery atherosclerosis[J]. Arterioscler Thromb

Vasc Biol，2017，37（7）：1415-1422.

[42] ZHAO S，WANG Y，MU Y，et al. Prevalence of

dyslipidaemia in patients treated with lipid-lowering

agents in China：results of the DYSlipidemia

International Study（DYSIS）[J]. Atherosclerosis，

2014，235（2）：463-469.

[43] WANG A，YANG Y，SU Z，et al. Association of

oxidized low-density lipoprotein with prognosis of

stroke and stroke subtypes[J]. Stroke，2017，48（1）：

91-97.

[44] YAMASHITA S，MASUDA D，OHAMA T，et

al. Rationale and design of the PROSPECTIVE

trial：probucol trial for secondary prevention of

atherosclerotic events in patients with prior coronary

heart disease[J]. J Atheroscler Thromb，2016，23（6）：

746-756.

[45] GIUGLIANO R P，WIVIOTT S D，BLAZING M

A，et al. Long-term safety and efficacy of achieving

very low levels of low-density lipoprotein cholesterol：

a prespecified analysis of the IMPROVE-IT trial[J].

JAMA Cardiol，2017，2（5）：547-555.

[46] SABATINE M S，GIUGLIANO R P，KEECH A C，

et al. Evolocumab and clinical outcomes in patients

with cardiovascular disease[J]. N Engl J Med，2017，

376（18）：1713-1722.